News

Adrenomed closes €24 million financing led by Wellington Partners and HBM

Details

Adrenomed AG, the vascular integrity company, today announced the closing of a €24 million series D financing round. The new funds will be invested in the clinical development program of lead product candidate Adrecizumab. Adrecizunab is currently tested in a phase II clinical trial in patients with early septic shock and elevated plasma Adrenomedullin concentrations (bio-ADM). 

Themis publishes compelling Phase 2 results for lead vaccine candidate against Chikungunya fever in "The Lancet"

Details

The recently completed Phase 2 clinical trial was designed to assess the safety, tolerability and immunogenicity of its lead vaccine candidate (MV-CHIK) to protect against Chikungunya fever, a mosquito-transmitted disease that has no current treatment or prevention options. The primary endpoint, defined as the presence of neutralizing antibodies against Chikungunya, four weeks after administration of one or two MV-CHIK injections, was met across all treatment groups. 

Themis announces exclusive licensing agreement with Max-Planck-Innovation to develop and commercialize oncolytic virotherapies

Details

Themis announced today that it has entered into a license agreement with Max-Planck-Innovation GmbH, the technology transfer agency of the Max Planck Society in Germany, granting it exclusive worldwide license to develop, manufacture and commercialize therapies based on an oncolytic measles virus platform that was jointly developed by the Eberhard-Karls-University Tübingen and the Max Planck Institute for Biochemistry. 

  1. sphingotec raises €20 million from HBM and Wellington Partners
  2. Carisma Therapeutics announces $53 million Series A financing
  3. TRiCares closes €22 million Series B financing round
  4. 4SC: Yakult Honsha joins pivotal RESMAIN study of resminostat in CTCL
© Wellington Partners, 2018.